Cargando…

Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma

BACKGROUND: Ipilimumab is an approved immunotherapy that has shown an overall survival benefit in patients with cutaneous metastatic melanoma in two phase III trials. As results of registrational trials might not answer all questions regarding safety and efficacy of ipilimumab in patients with advan...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zimmer, Lisa, Eigentler, Thomas K., Kiecker, Felix, Simon, Jan, Utikal, Jochen, Mohr, Peter, Berking, Carola, Kämpgen, Eckhart, Dippel, Edgar, Stadler, Rudolf, Hauschild, Axel, Fluck, Michael, Terheyden, Patrick, Rompel, Rainer, Loquai, Carmen, Assi, Zeinab, Garbe, Claus, Schadendorf, Dirk
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4635983/ https://www.ncbi.nlm.nih.gov/pubmed/26541511 http://dx.doi.org/10.1186/s12967-015-0716-5

Ejemplares similares

Phase II DeCOG-Study of Ipilimumab in Pretreated and Treatment-Naïve Patients with Metastatic Uveal Melanoma
por: Zimmer, Lisa, et al.
Publicado: (2015)

Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients
por: Amaral, Teresa, et al.
Publicado: (2020)

Chemosensitivity-directed therapy compared to dacarbazine in chemo-naive advanced metastatic melanoma: a multicenter randomized phase-3 DeCOG trial
por: Ugurel, Selma, et al.
Publicado: (2017)

Impact of a preceding radiotherapy on the outcome of immune checkpoint inhibition in metastatic melanoma: a multicenter retrospective cohort study of the DeCOG
por: Knispel, Sarah, et al.
Publicado: (2020)

Preferences of German melanoma patients for interferon (IFN) α-2b toxicities (the DeCOG “GERMELATOX survey”) versus melanoma recurrence to quantify patients’ relative values for adjuvant therapy
por: Kaehler, Katharina C., et al.
Publicado: (2016)

Response durability after cessation of immune checkpoint inhibitors in patients with metastatic Merkel cell carcinoma: a retrospective multicenter DeCOG study
por: Stege, H. M., et al.
Publicado: (2021)

Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCOG study of 84 patients
por: Leiter, Ulrike, et al.
Publicado: (2020)

Early Exanthema Upon Vemurafenib Plus Cobimetinib Is Associated With a Favorable Treatment Outcome in Metastatic Melanoma: A Retrospective Multicenter DeCOG Study
por: Kähler, Katharina C., et al.
Publicado: (2021)

Correlation of tumor PD-L1 expression in different tissue types and outcome of PD-1-based immunotherapy in metastatic melanoma – analysis of the DeCOG prospective multicenter cohort study ADOREG/TRIM
por: Placke, Jan-Malte, et al.
Publicado: (2023)

Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG
por: Franklin, Cindy, et al.
Publicado: (2023)

Patterns of care and follow-up care of patients with uveal melanoma in German-speaking countries: a multinational survey of the German Dermatologic Cooperative Oncology Group (DeCOG)
por: Steeb, Theresa, et al.
Publicado: (2020)

Impact of radiotherapy and sequencing of systemic therapy on survival outcomes in melanoma patients with previously untreated brain metastasis: a multicenter DeCOG study on 450 patients from the prospective skin cancer registry ADOREG
por: Franklin, Cindy, et al.
Publicado: (2022)

Dacarbazine and interferon α with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG)
por: Hauschild, A, et al.
Publicado: (2001)

The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network
por: Voskens, Caroline J., et al.
Publicado: (2013)

COMBI-r: A Prospective, Non-Interventional Study of Dabrafenib Plus Trametinib in Unselected Patients with Unresectable or Metastatic BRAF V600-Mutant Melanoma
por: Berking, Carola, et al.
Publicado: (2023)

Prognosis of Patients With Stage III Melanoma According to American Joint Committee on Cancer Version 8: A Reassessment on the Basis of 3 Independent Stage III Melanoma Cohorts
por: Garbe, Claus, et al.
Publicado: (2020)

Patterns of response with talimogene laherparepvec in combination with ipilimumab or ipilimumab alone in metastatic unresectable melanoma
por: Chesney, Jason, et al.
Publicado: (2019)

Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study
por: Heppt, Markus V., et al.
Publicado: (2019)

Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients
por: Hecht, Markus, et al.
Publicado: (2018)

Real-World Therapy with Pembrolizumab: Outcomes and Surrogate Endpoints for Predicting Survival in Advanced Melanoma Patients in Germany
por: Mohr, Peter, et al.
Publicado: (2022)

Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment
por: Garbe, Claus, et al.
Publicado: (2022)

Overall survival of patients with chemotherapy-naive advanced melanoma treated with ipilimumab 3 mg/kg in clinical trials
por: Dummer, Reinhard, et al.
Publicado: (2014)

Evaluation of real-world treatment outcomes in patients with distant metastatic Merkel cell carcinoma following second-line chemotherapy in Europe
por: Becker, Jürgen C., et al.
Publicado: (2017)

The efficacy of re-challenge with BRAF inhibitors after previous progression to BRAF inhibitors in melanoma: A retrospective multicenter study
por: Tietze, Julia K., et al.
Publicado: (2018)

Which melanoma patient carries a BRAF-mutation? A comparison of predictive models
por: Eigentler, Thomas, et al.
Publicado: (2016)

Treatment of disseminated ocular melanoma with sequential fotemustine, interferon α, and interleukin 2
por: Becker, J C, et al.
Publicado: (2002)

Treatment management for BRAF-mutant melanoma patients with tumor recurrence on adjuvant therapy: a multicenter study from the prospective skin cancer registry ADOREG
por: Haist, Maximilian, et al.
Publicado: (2023)

Clinical and molecular characteristics associated with response to therapeutic PD-1/PD-L1 inhibition in advanced Merkel cell carcinoma
por: Spassova, Ivelina, et al.
Publicado: (2022)

Willingness to pay for a cure of low-risk melanoma patients in Germany
por: Augustin, Matthias, et al.
Publicado: (2018)

Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Re-Induction following Resistance or Toxicity
por: Koch, Elias A. T., et al.
Publicado: (2022)

Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Patterns of Response and Survival According to the Presence of Hepatic and Extrahepatic Metastasis
por: Koch, Elias A. T., et al.
Publicado: (2021)

Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study
por: Dalle, Stéphane, et al.
Publicado: (2021)

Skin Cancer Classification Using Convolutional Neural Networks: Systematic Review
por: Brinker, Titus Josef, et al.
Publicado: (2018)

Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial
por: Chesney, Jason A, et al.
Publicado: (2023)

Extension of the COG and arCOG databases by amino acid and nucleotide sequences
por: Meereis, Florian, et al.
Publicado: (2008)

The outweigh of toxicity versus risk of recurrence for adjuvant interferon therapy: a survey in German melanoma patients and their treating physicians
por: Kähler, Katharina C., et al.
Publicado: (2018)

Systematic Review of Medical Treatment in Melanoma: Current Status and Future Prospects
por: Garbe, Claus, et al.
Publicado: (2011)

The Golgi's central COG
por: Wells, William A.
Publicado: (2002)

Cogging in the Fermilab Booster
por: Herrup, D A
Publicado: (1999)

New Cogs for Old
por: Harrop, Tom
Publicado: (1969)

Cannot write session to /tmp/vufind_sessions/sess_k8eeirflvq1nm4r7i5tvhu83b9